dc.contributor.author | Ghorbanihaghjo, A | |
dc.contributor.author | Javadzadeh, A | |
dc.contributor.author | Rashtchizadeh, N | |
dc.contributor.author | Sorkhabi, R | |
dc.contributor.author | Khalili, H | |
dc.contributor.author | Rahimi-Ardabili, B | |
dc.date.accessioned | 2018-08-26T09:31:35Z | |
dc.date.available | 2018-08-26T09:31:35Z | |
dc.date.issued | 2014 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57107 | |
dc.description.abstract | Calcification and inflammation are among the important cases of exudative age-related macular degeneration (E-ARMD). The aim of the present study was to elucidate if there is any relationship between serum Osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kappa B ligand (RANK-ligand) and E-ARMD. In a cross-sectional study, we compared 45 E-ARMD patients with 45 matched controls. Diagnosis was confirmed by fluorescein angiography. Serum samples were analyzed for OPG, RANK-ligand, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglyceride (TG). The levels of OPG and RANK-ligand were measured by ELISA methods. The mean age was 72.0±11.5 years in the E-ARMD group and 68.2±8.9 years in the control group (p=0.09). The level of serum OPG was 132.10±75.49 pg/ml in the E-ARMD group and 94.88±61.65 pg/ml in the control subjects. E-ARMD patients had significantly high levels of OPG (p=0.012), as well as significantly high levels of LDL-C and TC (p=0.001 and p=0.005, respectively). We could not find any significant difference in RANK-ligand, HDL-C, or TG between two study groups (p>0.05). To the best of our knowledge, this is the first study investigating the levels of OPG in E-ARMD patients. The present study showed that E-ARMD patients had high levels of serum OPG. It may act as a protective factor for E-ARMD or only as a secondary phenomenon of different processes of E-ARMD. Further prospective studies would be necessary for prognostic and predictive significance of OPG in patients affected by E-ARMD. © 2014 Tehran University of Medical Sciences. All rights reserved. | |
dc.language.iso | English | |
dc.relation.ispartof | Acta Medica Iranica | |
dc.subject | cholesterol | |
dc.subject | high density lipoprotein cholesterol | |
dc.subject | immunoglobulin enhancer binding protein | |
dc.subject | low density lipoprotein cholesterol | |
dc.subject | osteoprotegerin | |
dc.subject | triacylglycerol | |
dc.subject | aged | |
dc.subject | article | |
dc.subject | biomicroscopy | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | cross-sectional study | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | female | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | male | |
dc.subject | retina fluorescein angiography | |
dc.subject | retina macula age related degeneration | |
dc.subject | subretinal neovascularization | |
dc.subject | tonometry | |
dc.subject | visual acuity | |
dc.subject | Age Factors | |
dc.subject | Aged | |
dc.subject | Angiography | |
dc.subject | Case-Control Studies | |
dc.subject | Cross-Sectional Studies | |
dc.subject | Enzyme-Linked Immunosorbent Assay | |
dc.subject | Exudates and Transudates | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Iran | |
dc.subject | Macular Degeneration | |
dc.subject | Male | |
dc.subject | Osteoprotegerin | |
dc.subject | RANK Ligand | |
dc.title | Osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand in exudative age-related macular degeneration | |
dc.type | Article | |
dc.citation.volume | 52 | |
dc.citation.issue | 4 | |
dc.citation.spage | 265 | |
dc.citation.epage | 270 | |
dc.citation.index | Scopus | |